NCT06228001Recruiting
Holter of Movement in Patients With Amyotrophic Lateral Sclerosis.
Source: ClinicalTrials.gov · Last updated 19 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
ActiALS is a multicentric academic study. Patients with amyotrophic lateral sclerosis (ALS) may be included on a voluntary basis. The investigators plan to include a group of approximately 30 patients with ALS. The investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 14 Dec 2023
- Start date
- 1 May 2023
- Primary completion date
- Jan 2028
- Lead sponsor
- Centre Hospitalier Universitaire de Liege
- Diseases
- ALS (motor neurone disease)
- NCT number
- NCT06228001
What you commit to
- Study type: Observational
- Planned participants: 30
- From 1 May 2023 to the primary completion date, Jan 2028
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any other previous or present pathology having an impact on motor function.
- Recent surgery or trauma (less than 6 months) in the upper or lower limbs.
- Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory pathology in the three weeks preceding inclusion.
Other illness
- Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection.
Other
- Patients participating in an interventional clinical trial.
Who the study is looking for
- Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm.
- Over 18 years old.
- Signed informed consent
- If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the study period.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Katholieke Universiteit Leuven Coordinator of this site? Confirm its status | Leuven | Belgium | Recruiting |
| Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle Coordinator of this site? Confirm its status | Liège | Belgium | Recruiting |
| Galaa Military Medical Complex Coordinator of this site? Confirm its status | Cairo | Egypt | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.